drugset

drugset / Trial / NCT06830850

A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer

NCT06830850 ↗

Phase 1 Recruiting 25 enrolled Atridia Pty Ltd.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of 5041-103 in Subjects with Metastatic Castration-resistant Prostate Cancer.

Timeline

Start: 2025-06-15
Primary completion: 2026-12-30
Completion: 2027-03-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS-5041	Other / unclassified	240 mg	Oral

Indications